Antibiotic and phage therapy for resistant lung infections in cystic fibrosis
Part of Digestive system, Genetic & congenital, Infections, Lungs & breathing clinical trials.
This study tests a new treatment that combines regular antibiotics with a special virus that attacks bacteria (called a phage) to fight lung infections that do not respond to standard antibiotics. It aims to see if this combination is safe and might help people with cystic fibrosis who have stubborn lung infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have cystic fibrosis.
- Your sputum (mucus coughed up) must show one of these bacteria: Pseudomonas, Klebsiella, Stenotrophomonas, E. coli, Staph, or Achromobacter.
- Your lung function (measured by a breathing test) must be at least 40% of what is expected for your age and height.
- If your lung function is above 40%, you must have had at least one lung infection flare-up in the past year that needed IV antibiotics, or have severe lung damage on X-rays.
- You must have had a successful IV antibiotic treatment at home within the last 5 years (this can be waived by the study doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
This study tests whether giving you a mixture of viruses (called phages) that specifically target the bacteria Achromobacter can help treat your chronic lung infection. You would breathe in the phages, and the study will check if this is safe and helps improve your breathing.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This trial tests a treatment that uses special viruses (called phages) to kill antibiotic-resistant bacteria causing pneumonia in people on ventilators. If you're eligible, this new approach might help fight the infection when standard antibiotics aren't working well.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This trial tests a treatment using bacteriophages (viruses that attack specific bacteria) to fight a tough lung infection called Mycobacterium abscessus that doesn't respond to usual antibiotics. If you have this infection, this treatment might offer a new way to clear it.
Hear when a new Klebsiella Pneumoniae Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.